browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
3f753f3b-e344-4f93-984d-9e1578069e21
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 20:09:55
Income (reported)
$50,000
Expenses (reported)
—
Filing document
Open on lda.senate.gov

Registrant (lobbying firm)

ARTEMIS POLICY GROUP LLC

Lobbying firm

Contact
ELIZABETH KARAN
Phone
+1 612-202-3240
Address
zip:20001, city:Washington, state:DC, street:912 East Capitol Street NE

Client

NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION)

Nonprofit supporting patients with inheritable bleeding disorders.

State
NY
Country
US
Government-entity client
false
Effective date
2020-04-01

Issues lobbied + lobbyists

MMM — Medicare/Medicaid

Implementation of H.R. 1, One Big Beautiful Bill Act Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Preserving and expanding access to Medicaid Issues related to 1115 of the Social Security Act; policies related to work requirements in Medicaid Comments on RE: CMS-5545-P: Global Benchmark for Efficient Drug Pricing (GLOBE) Model Comments on CMS-5546-P: Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

Blood and plasma safety and awareness Bleeding disorders awareness

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

INS — Insurance

Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of the Affordable Care Act The HELP Copays Act (S. 864, H.R. 6423) Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model Policies related to copay accumulator adjustor and maximizer programs Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46, HR 1834 Comments on Proposed Rule: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P)

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Labor, Dept of (DOL); SENATE; Treasury, Dept of

BUD — Budget/Appropriations

Funding for federal hemophilia programs in FY26 and FY27 House and Senate Labor-HHS Appropriations bills NIH FY26 and FY27 appropriations

Lobbyists:

Government entities lobbied: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

PHA — Pharmacy

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

MED — Medical/Disease Research/Clinical Labs

Hemophilia research, prevention, surveillance and service programs and issues; advancing care for women and girls with bleeding disorders

Lobbyists:

Government entities lobbied: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.